phospho-IRS1 (Ser636 + Ser639)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 3201R
英文名称phospho-IRS1 (Ser636 + Ser639)
中文名称磷酸化胰岛素受体底物-1抗体
别 名IRS1 (phospho S636); p-IRS1 (phospho S636); IRS1 (phospho S639); p-IRS1 (phospho S639); IRS-1(Phospho-Ser636); IRS-1(Phospho-Ser639); p-IRS1; IRS1(phospho-Ser636/639); HIRS 1; HIRS1; Insulin Receptor Substrate 1; IRS-1; IRS 1; IRS1; OTTHUMP00000164234; IRS1_HUMAN.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 神经生物学 信号转导 转录调节因子 糖尿病 细胞膜蛋白
抗体来源Rabbit
克隆类型Polyclonal
phospho-IRS1 (Ser636 + Ser639)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 Flow-Cyt=1μg /test （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量132kDa
细胞定位细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human IRS1 around the phosphorylation site of Ser636/639 [PM(p-S)PK(p-S)VS]:PM(p-S)PK(p-S)VS
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-IRS1 (Ser636 + Ser639)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
Insulin receptor substrates (IRS) are responsible for several insulin related activities, such as glucose homeostasis, cell growth, cell transformation, apoptosis and insulin signal transduction. Serine/threonine phosphorylation of IRS1 has been demonstrated to be a negative regulator of insulin signaling and is responsible for its degradation, although IRS1 degradation pathways are not well understood. IRS1 has also been shown to be constitutively activated in cancers such as breast cancer, Wilm's tumors, and adrenal cortical carcinomas, thus making IRS1 phosphorylation and subsequent degradation an attractive therapeutic target. To date there have been four subtypes identified: IRS1, 2, 3 and 4, with IRS1 being widely expressed.
Function:
May mediate the control of various cellular processes by insulin. When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit.
Subunit:
Interacts with UBTF and PIK3CA. Interacts (via phosphorylated YXXM motifs) with PIK3R1. Interacts with ROCK1 and FER. Interacts (via PH domain) with PHIP. Interacts with GRB2. Interacts with SOCS7. Interacts (via IRS-type PTB domain) with IGF1R and INSR (via the tyrosine-phosphorylated NPXY motif). Interacts with ALK.
Subcellular Location:
Membrane; Single-pass type I membrane protein.
Tissue Specificity:
Isoform Long and isoform Short are predominantly expressed in tissue targets of insulin metabolic effects: liver, adipose tissue and skeletal muscle but are also expressed in the peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta vascular endothelium, fibroblasts, monocytes, granulocytes, erythrocytes and skin. Isoform Short is preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Overexpressed in several tumors, including breast, colon, lung, ovary, and thyroid carcinomas.
Post-translational modifications:
Serine phosphorylation of IRS1 is a mechanism for insulin resistance. Ser-312 phosphorylation inhibits insulin action through disruption of IRS1 interaction with the insulin receptor.
Phosphorylation of Tyr-896 is required for GRB2-binding. Phosphorylated by ALK. Phosphorylated at Ser-270, Ser-307, Ser-636 and Ser-1101 by RPS6KB1; phosphorylation induces accelerated degradation of IRS1.
DISEASE:
Polymorphisms in IRS1 may be involved in the etiology of non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853].
Similarity:
Contains 1 IRS-type PTB domain.
Contains 1 PH domain.
SWISS:
P35568
Gene ID:
3667
phospho-IRS1 (Ser636 + Ser639)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-IRS1 (Ser636 + Ser639)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 GPR19/GPR4 G蛋白偶联受体19/GPCR GPR4抗体
合格 合格 GPR20 G蛋白偶联受体20抗体
合格 GPR25 G蛋白偶联受体25抗体
合格 GPR27 G蛋白偶联受体27抗体
合格 MCL1 髓样细胞白血病-1抗体
合格 GPR31 G蛋白偶联受体31抗体
合格 GPR37 G蛋白偶联受体37/帕金森相关内皮素受体样受体抗体
合格 GPR44 G蛋白偶联受体44抗体
合格 GPR45 G蛋白偶联受体45抗体
合格 合格 Beclin 1 Bcl-2同源结构域蛋白抗体
合格 合格 GPR58 G蛋白偶联受体58抗体
合格 phospho-Histone H1oo (Ser20) 磷酸化组蛋白H1FOO抗体
合格 Histone H2B.s 组蛋白H2B.s抗体
合格 Guanylyl Cyclase alpha 1 鸟苷酸环化酶α1/GCS-α-1抗体
合格 Guanylyl Cyclase alpha 2 鸟苷酸环化酶α2/GCS-α-2抗体
合格 ZAR1 受精卵抑制蛋白1抗体
合格 APOJ 载脂蛋白J抗体
合格 ZAR1L 受精卵抑制蛋白1样蛋白抗体
合格 ZBED2 锌指蛋白BED抗体
合格 合格 ZBED3 锌指蛋白BED3抗体
合格 ZADH1 锌结合乙醇脱氢酶结构域蛋白1抗体
合格 zbtb11 锌指蛋白913抗体
合格 ZBTB12 锌指蛋白ZBTB12抗体
合格 ZBTB3 锌指蛋白ZBTB3抗体
合格 合格 ZBTB25 锌指蛋白46抗体
合格 Integrin Alpha V + Beta 5 整合素αVβ5抗体
合格 ZBTB3 锌指蛋白ZBTB3抗体
合格 ZBTB34 锌指蛋白ZBTB34抗体
合格 ZBTB38 锌指蛋白ZBTB38抗体
合格 ZBTB40 锌指蛋白923抗体
合格 ZBTB41 锌指蛋白924抗体
合格 合格 ZBTB42 锌指蛋白925抗体
合格 ZBTB6 锌指蛋白ZBTB6抗体